Zhang HK - Search Results

1

Scaffold Hopping Strategy to Identify Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.

Wang W, He J, Yang J, Zhang C, Cheng Z, Zhang Y, Zhang Q, Wang P, Tang S, Wang X, Liu M, Lu W, Zhang HK. Wang W, et al. Among authors: zhang c, zhang q, zhang hk, zhang y. J Med Chem. 2022 Jun 9;65(11):7896-7917. doi: 10.1021/acs.jmedchem.2c00448. Epub 2022 May 31. J Med Chem. 2022. PMID: 35640059

2

Chemistry and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.

Zhang H, Tückmantel W, Eaton JB, Yuen PW, Yu LF, Bajjuri KM, Fedolak A, Wang D, Ghavami A, Caldarone B, Paterson NE, Lowe DA, Brunner D, Lukas RJ, Kozikowski AP. Zhang H, et al. J Med Chem. 2012 Jan 26;55(2):717-24. doi: 10.1021/jm201157c. Epub 2012 Jan 10. J Med Chem. 2012. PMID: 22171543 Free PMC article.

3

Synthesis and biological evaluation of novel hybrids of highly potent and selective α4β2-Nicotinic acetylcholine receptor (nAChR) partial agonists.

Zhang HK, Eaton JB, Fedolak A, Gunosewoyo H, Onajole OK, Brunner D, Lukas RJ, Yu LF, Kozikowski AP. Zhang HK, et al. Eur J Med Chem. 2016 Nov 29;124:689-697. doi: 10.1016/j.ejmech.2016.09.016. Epub 2016 Sep 9. Eur J Med Chem. 2016. PMID: 27639361 Free PMC article.

4

Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based approaches.

Wu Z, Lu W, Yu W, Wang T, Li W, Liu G, Zhang H, Pang X, Huang J, Liu M, Cheng F, Tang Y. Wu Z, et al. Pharmacol Res. 2018 Mar;129:400-413. doi: 10.1016/j.phrs.2017.11.005. Epub 2017 Nov 10. Pharmacol Res. 2018. PMID: 29133212

5

Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.

Jiang XW, Jiang BE, Liu H, Liu ZT, Hu LL, Liu M, Lu W, Zhang HK. Jiang XW, et al. Among authors: zhang hk. Eur J Med Chem. 2018 Oct 5;158:123-133. doi: 10.1016/j.ejmech.2018.08.075. Epub 2018 Aug 31. Eur J Med Chem. 2018. PMID: 30212763

6

Discovery and Characterization of 1H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.

Yang JJ, Yu WW, Hu LL, Liu WJ, Lin XH, Wang W, Zhang Q, Wang PL, Tang SW, Wang X, Liu M, Lu W, Zhang HK. Yang JJ, et al. Among authors: zhang q, zhang hk. J Med Chem. 2020 Jan 23;63(2):569-590. doi: 10.1021/acs.jmedchem.9b01269. Epub 2020 Jan 2. J Med Chem. 2020. PMID: 31855426

7

Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer.

Lu W, Yu W, He J, Liu W, Yang J, Lin X, Zhang Y, Wang X, Jiang W, Luo J, Zhang Q, Yang H, Peng S, Yi Z, Ren S, Chen J, Siwko S, Nussinov R, Cheng F, Zhang H, Liu M. Lu W, et al. EMBO Mol Med. 2021 Jan 11;13(1):e12798. doi: 10.15252/emmm.202012798. Epub 2020 Dec 7. EMBO Mol Med. 2021. PMID: 33283987 Free PMC article.

8

From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.

Jiang BE, Jiang X, Zhang Q, Liang Q, Qiu ZL, Sun XB, Yang JJ, Chen S, Yi C, Chai X, Liu M, Yu LF, Lu W, Zhang HK. Jiang BE, et al. Among authors: zhang q, zhang hk. J Med Chem. 2021 Jan 14;64(1):385-403. doi: 10.1021/acs.jmedchem.0c01023. Epub 2020 Dec 31. J Med Chem. 2021. PMID: 33382613

9

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.

Jiang BE, Hu J, Liu H, Liu Z, Wen Y, Liu M, Zhang HK, Pang X, Yu LF. Jiang BE, et al. Among authors: zhang hk. Eur J Med Chem. 2022 Jan 5;227:113893. doi: 10.1016/j.ejmech.2021.113893. Epub 2021 Oct 2. Eur J Med Chem. 2022. PMID: 34656899

10

Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.

Peng S, Hu P, Xiao YT, Lu W, Guo D, Hu S, Xie J, Wang M, Yu W, Yang J, Chen H, Zhang X, Zhu Y, Wang Y, Yang Y, Zhu G, Chen S, Wang J, Zhang B, Chen W, Wu H, Sun Z, Ding T, Zhang H, Yi Z, Liu M, Ren S. Peng S, et al. Clin Cancer Res. 2022 Feb 1;28(3):552-567. doi: 10.1158/1078-0432.CCR-21-0299. Epub 2021 Nov 5. Clin Cancer Res. 2022. PMID: 34740924

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

220 results

Search Page